Qlucore Diagnostics Solution for Pediatric Acute Leukemia Sold to First Customer
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Qlucore is pleased to announce that its CE-marked (IVDR) diagnostic test, Qlucore Diagnostics 1.0 BCP-ALL, has been sold to its first customer. This milestone follows the successful launch at the end of February 2025.
Qlucore Diagnostics BCP-ALL is the first CE-marked (IVDR) diagnostic test specifically designed to improve the diagnosis of pediatric acute leukemia. Delivered as a software solution, it leverages AI-based machine learning to provide accurate and reliable results. Sales of Qlucore Diagnostics 1.0 for BCP-ALL commenced in Europe at the end of February 2025 and the first customer to be announced is Rigshospitalet, the largest teaching and public hospital in Denmark.
Improvement in diagnostics is a prerequisite for advancing precision medicine, leading to targeted therapies and better patient outcomes. Qlucore Diagnostics 1.0 for BCP-ALL is the first test from Qlucore. Development is ongoing for tests addressing lung cancer, bladder cancer and acute myeloid leukemia (AML).
“We are happy to announce that Rigshospitalet will be our first Qlucore Diagnostics customer. We are confident that their leadership will inspire other clinical laboratories to adopt our CE-marked diagnostic test designed to improve the diagnosis and treatment of pediatric acute leukemia,” says Carl-Johan Ivarsson, CEO of Qlucore.